"" Stock Sale by Johnson & Johnson EVP
Jennifer L. Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine at Johnson & Johnson, sold approximately $3.95 million worth of company stock on August 17, 2026, following the exercise of employee stock options.
She acquired 15,000 shares of common stock at an exercise price of $115.67 per share and subsequently sold the same number of shares at a weighted average price of $263.36. This sale is part of a larger transaction, in which she directly holds 194,451.001 shares of Johnson & Johnson common stock and retains 28,712 employee stock options.
Recent Ratings and Price Targets
Freedom Capital upgraded Johnson & Johnson to a Buy rating, raising its price target to $280 from $230, citing the company's strong quarterly performance. Guggenheim increased its price target for the company to $287 from $270, while Raymond James raised its price target to $280 from $265. These developments reflect the ongoing assessments and strategic adjustments by analysts and firms in response to the companies' recent performances and innovations.
Background
The recent performance of Johnson & Johnson, including revenue from TREMFYA exceeding projections by approximately $400 million, has been a key factor in the recent upgrades to the company's stock rating. Additionally, the FDA approval of the Ottava robotic surgery platform has also contributed to the company's strong quarterly performance. However, it is worth noting that Piper Sandler maintained a Neutral rating for Medtronic with a price target of $85, citing the company's expected lead in PFA catheters and mapping by 2028.
Categories: [bitcoin, ethereum, markets, defi-news, regulation, nfts, altcoins, mining, exchanges, security] Tags: jnj, jennifer taubert, johnson & johnson, stock sale, buy rating, price target image_prompt: bold graphic of Johnson & Johnson logo
